BretEdward BuckleyFridayMD

Oncology • Duluth, MN

Hematologic Oncology, Neuro-Oncology

Physician Scientist & Member - Essentia Medical Group-Duluth

Join to view full profile

Dr. Friday is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Friday's full profile

Already have an account?

Office
400 East 3rd St
Duluth, MN 55805
Phone+1 218-786-8364
Is this information wrong?

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2005 - 2008
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2002 - 2005
Emory University School of MedicineClass of 2002

Certifications & Licensure

WI State Medical License 2009 - 2025
MN State Medical License 2003 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Start of enrollment: 2013 May 15
Completed
Phase 3
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Completed
Phase 1, Phase 2
Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma Start of enrollment: 2013 Jun 01
Completed
Phase 3
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Start of enrollment: 2013 Jul 31
Completed
Phase 2
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Start of enrollment: 2013 Sep 20
Active, not recruiting
Phase 2
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
Active, not recruiting
Phase 2
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Active, not recruiting
Phase 3
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Start of enrollment: 2014 Mar 29
Active, not recruiting
Phase 3
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Active, not recruiting
Phase 3
Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer Start of enrollment: 2016 Feb 25
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
Safety of Extending The Routine Flushing Of Implanted Port Devices From 4 Weeks To 12 Start of enrollment: 2022 Oct 11
Recruiting
Not Applicable
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

9 citations
Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial.
Robert S Krouse, Garnet L Anderson, Kathryn B Arnold, Cynthia A Thomson, Valentine N Nfonsam, Mazin F Al-Kasspooles, Joan L Walker, Virginia Sun, Angeles Alvarez Secor...> ;The Lancet. Gastroenterology & Hepatology. 2023 Oct 1
A five arm natural history study of nasal vestibulitis.
Elizabeth J Cathcart-Rake, David Zahrieh, Deanne Smith, Susan Young, Shaylene McCue, Amanda O'Connor, Stephan Thomé, Mario Lacouture, Terra Register, Jill Piens, Bret ...> ;Cancer Medicine. 2023 Apr 1
3 citations
Feasibility of preemptive pharmacogenetic testing in colorectal cancer patients within a community oncology setting
Tiana Luczak, Paul J Schillo, Colleen M. Renier, Stephen C. Waring, Bret Edward Buckley Friday> ;Journal of Oncology Pharmacy Practice. 2021 Apr 15
1 citations
Natural history of nasal vestibulitis associated with paclitaxel, docetaxel, and other chemotherapy agents: a Minnesota Cancer Clinical Trials Network (MNCCTN) study
Elizabeth J. Cathcart-Rake, David Zahrieh, Deanne Smith, Susan Young, Shaylene A. McCue, Amanda O’Connor, Stephan D. Thomé, Mario E. Lacouture, Terra Register, Jill Pi...> ;Supportive Care in Cancer. 2021 Apr 13
6 citations
Delivering Equitable Care to Underserved Neuro-oncology Populations.
Alyx B. Porter, Ugonma Chukwueke, Aaron Mammoser, Bret Edward Buckley Friday, Shawn L. Hervey-Jumper> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2021 Apr 8
52 citations
Barriers to accrual and enrollment in brain tumor trials.
Eudocia Q. Lee, Ugonma Chukwueke, Shawn L. Hervey-Jumper, John de Groot, Jose Pablo Leone, Terri Armstrong, Susan M. Chang, David Arons, Kathy Oliver, Kay Verble, Al M...> ;Neuro-Oncology. 2019 Sep 6
22 citations
Alisertib Demonstrates Significant Antitumor Activity in Bevacizumab Resistant, Patient Derived Orthotopic Models of Glioblastoma
Cheyne Kurokawa, Hirosha Geekiyanage, Cory Allen, Ianko D. Iankov, Mark A. Schroeder, Brett L. Carlson, Katrina K. Bakken, Jann N. Sarkaria, Jeffrey Ecsedy, A B D'Asso...> ;Journal of Neuro-Oncology. 2017 Jan 1
162 citations
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.
Bret Edward Buckley Friday, S. Keith Anderson, Jan C. Buckner, Chunrong Yu, Caterina Giannini, Francois J. Geoffroy, John Schwerkoske, Miroslaw Mazurczak, Howard Gross...> ;Neuro-Oncology. 2012 Feb 1
124 citations
BRAF V600E Disrupts AZD6244-Induced Abrogation of Negative Feedback Pathways between Extracellular Signal-Regulated Kinase and Raf Proteins
Bret B. Friday, Grace K. Dy, Paul D. Smith, Liang Wang, Stephen N. Thibodeau, Alex A. Adjei> ;Cancer Research. 2008 Aug 1
303 citations
Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy
Bret B. Friday, Alex A. Adjei> ;Clinical Cancer Research. 2008 Jan 15
187 citations
K-ras as a target for cancer therapy.
Bret B. Friday, Alex A. Adjei> ;Biochimica Et Biophysica Acta. 2005 Nov 25
Systemic Complications of Infective Endocarditis
Bret B. Friday, Arjun Deb> ;Circulation. 2005 Nov 15
97 citations
Calcineurin initiates skeletal muscle differentiation by activating MEF2 and MyoD
Bret B. Friday, Patrick O. Mitchell, Kristy M. Kegley, Grace K. Pavlath> ;Differentiation; Research in Biological Diversity. 2003 Apr 1
Join now to see all

Hospital Affiliations

Essentia Health DuluthDuluth, Minnesota
Essentia Health St. Mary's Medical CenterDuluth, Minnesota
Essentia Health St. Mary's Hospital of SuperiorSuperior, Wisconsin
Fairview Range Medical CenterHibbing, Minnesota
Essentia Health-VirginiaVirginia, Minnesota
Essentia Health Northern Pines Medical CenterAurora, Minnesota